Literature DB >> 27293089

Molecular Mechanisms and microRNAs in Osteosarcoma Pathogenesis.

N E Kushlinskii1, M V Fridman, E A Braga.   

Abstract

This review summarizes data on microRNA (miRNA) genomic organization, biogenesis, and functions in carcinogenesis. The roles of key genes and regulatory miRNAs in molecular mechanisms and signaling pathways involved in the development of osteosarcoma, the most aggressive type of bone tumor striking mainly in adolescence and early adulthood, are discussed in detail. The most critical pathways in osteosarcoma pathogenesis are the Notch, Wnt, NF-κB, p53, PI3K/Akt, and MAPK pathways. The balance between cell survival and apoptosis is determined by the Wnt and NF-κB pathways, as well as by the ratio between the activities of the MAPK and PI3K/Akt pathways. Several miRNAs (miR-21, -34a, -143, -148a, -195a, -199a-3p, -382) regulate multiple target genes, pathways, and processes essential for osteosarcoma pathogenesis. Data on the key genes and regulatory miRNAs involved in metastasis and tumor cell response to drug treatment are presented. Possible applications of miRNA in osteosarcoma diagnostics and treatment are discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27293089     DOI: 10.1134/S0006297916040027

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  48 in total

1.  Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis.

Authors:  Sofía Jerez; Héctor Araya; Daniel Hevia; Carlos E Irarrázaval; Roman Thaler; Andre J van Wijnen; Mario Galindo
Journal:  Gene       Date:  2019-06-06       Impact factor: 3.688

2.  MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.

Authors:  Wenjiong Hao; Wei Luo; Mangmang Bai; Jian Li; Xiaobin Bai; Jie Guo; Jinsong Wu; Maode Wang
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

3.  Long noncoding RNA LeXis promotes osteosarcoma growth through upregulation of CTNNB1 expression.

Authors:  Guijiang Wang; Tao Cui; Lishan Sun; Ningning Peng; Cheng Yang
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 4.  Exosomes in osteosarcoma research and preclinical practice.

Authors:  Xiao-Bo Zhang; Rui-Hao Zhang; Xin Su; Jin Qi; Yi-Cun Hu; Jin-Tao Shi; Kai Zhang; Ke-Ping Wang; Hai-Yu Zhou
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

5.  The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.

Authors:  Bingyi Tan; Zenong Yuan; Qingyu Zhang; Xu Xiqiang; Jun Dong
Journal:  J Appl Biomed       Date:  2021-09-24       Impact factor: 1.797

6.  miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

Authors:  Pan Jiang; Lianghao Mao; Xuan Lei; Chunshan Luo; Yiming Zhang; Xinyu Zhong; Zhenyu Yin; Xiaofeng Xu; Dapeng Li; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

7.  HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2.

Authors:  Peng Luo; Yan-Dong Zhang; Feng He; Chang-Jun Tong; Kai Liu; He Liu; Shi-Zhuang Zhu; Jian-Zhou Luo; Bing Yuan
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

8.  MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1.

Authors:  Dengkun Lv; Zhen Zhen; Defa Huang
Journal:  Exp Ther Med       Date:  2018-11-29       Impact factor: 2.447

9.  MicroRNA-873 inhibits the proliferation and invasion of endometrial cancer cells by directly targeting hepatoma-derived growth factor.

Authors:  Qin Wang; Weipei Zhu
Journal:  Exp Ther Med       Date:  2019-06-26       Impact factor: 2.751

10.  Development and validation of nomogram based on miR-203 and clinicopathological characteristics predicting survival after neoadjuvant chemotherapy and surgery for patients with non-metastatic osteosarcoma.

Authors:  Dong Cheng; Xubin Qiu; Ming Zhuang; Chenlei Zhu; Hongjun Zou; Ailiang Zhang
Journal:  Oncotarget       Date:  2017-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.